Omnitus, 20 mg 10 pcs

Pharmacodynamics
Butamirate, the active ingredient of Omnitus®, is a centrally acting cough suppressant. It is neither chemically nor pharmacologically related to opium alkaloids. It is not addictive or addictive.
It suppresses cough having direct influence on the coughing center. It has a bronchodilator effect (expands the bronchi). Helps ease breathing, improving spirometry (reduces airway resistance) and blood oxygenation (oxygenates blood).

Pharmacokinetics
Absorption is high. After oral administration of the modified-release tablet (50 mg), maximum concentration in plasma of the main metabolite (2-phenyl butyric acid) is observed after 9 hours and is 1.4 µg/ml.
Butamirate is hydrolyzed in plasma to 2-phenyl butyric acid and diethylaminoethoxyethanol. These metabolites also have antitussive activity and, like butamyrate, are largely (about 95%) bound to plasma proteins, which causes their long elimination half-life. 2-phenyl butyric acid is partially metabolized by hydroxylation at the para-position. There is no cumulation when taking the drug again.
Half-life is 13 hours. Excretion of the three metabolites occurs mainly through the kidneys; after conjugation in the liver, acidic metabolites are largely bound to glucuronic acid.

Indications

Dry cough of any etiology (with colds, flu, whooping cough and other conditions).

Cough suppression in preoperative and postoperative period, during surgery, bronchoscopy.

Active ingredient

Composition

How to take, the dosage

Special Instructions

Synopsis

Features

Contraindications

Side effects

Overdose

Symptoms: nausea, vomiting, drowsiness, diarrhea, dizziness, decreased blood pressure.

Treatment: orally – activated charcoal, saline laxatives, if necessary – symptomatic therapy.

Pregnancy use

It is contraindicated in lactation, pregnancy, children and adolescents under 6 years of age.

Similarities